|
1
|
Haase D, Germing U, Schanz J, et al: New
insights into the prognostic impact of the karyotype in MDS and
correlation with subtypes: evidence from a core dataset of 2124
patients. Blood. 110:4385–4395. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nimer SD: Myelodysplastic syndromes.
Blood. 111:4841–4851. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ebert BL, Galili N, Tamayo P, et al: An
erythroid differentiation signature predicts response to
lenalidomide in myelodysplastic syndrome. PLoS Med. 5:e352008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adès L, Boehrer S, Prebet T, et al:
Efficacy and safety of lenalidomide in intermediate-2 or high-risk
myelodysplastic syndromes with 5q deletion: results of a phase 2
study. Blood. 113:3947–3952. 2009.
|
|
5
|
Greenberg PL, Attar E, Bennett JM,
Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K,
Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson
M, Nimer SD, O’Donnell MR, Schroeder MA, Shami PJ, Stone RM,
Thompson JE and Westervelt P; National Comprehensive Cancer
Network. NCCN Clinical Practice Guidelines in Oncology:
myelodysplastic syndromes. J Natl Compr Canc Netw. 9:30–56.
2011.PubMed/NCBI
|
|
6
|
Haslett PA, Corral LG, Albert M and Kaplan
G: Thalidomide costimulates primary human T lymphocytes,
preferentially inducing proliferation, cytokine production, and
cytotoxic responses in the CD8+ subset. J Exp Med. 187:1885–1892.
1998.PubMed/NCBI
|
|
7
|
Davies FE, Raje N, Hideshima T, et al:
Thalidomide and immunomodulatory derivatives augment natural killer
cell cytotoxicity in multiple myeloma. Blood. 98:210–216. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang DH, Liu N, Klimek V, et al:
Enhancement of ligand-dependent activation of human natural killer
T cells by lenalidomide: therapeutic implications. Blood.
108:618–621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
List A, Kurtin S, Roe DJ, et al: Efficacy
of lenalidomide in myelodysplastic syndromes. N Engl J Med.
352:549–557. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
List A, Dewald G, Bennett J, et al;
Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in
the myelodysplastic syndrome with chromosome 5q deletion. N Engl J
Med. 355:1456–1465. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
List AF: Lenalidomide - the phoenix rises.
N Engl J Med. 357:2183–2186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raza A, Reeves JA, Feldman EJ, et al:
Phase 2 study of lenalidomide in transfusion-dependent, low-risk,
and intermediate-1 risk myelodysplastic syndromes with karyotypes
other than deletion 5q. Blood. 111:86–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sekeres MA, Maciejewski JP, Giagounidis
AA, et al: Relationship of treatment-related cytopenias and
response to lenalidomide in patients with lower-risk
myelodysplastic syndromes. J Clin Oncol. 26:5943–5949. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Revicki DA, Brandenburg NA, Muus P, Yu R,
Knight R and Fenaux P: Health-related quality of life outcomes of
lenalidomide in transfusion-dependent patients with Low- or
Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q
deletion: Results from a randomized clinical trial. Leuk Res.
37:259–265. 2013. View Article : Google Scholar
|
|
15
|
Komrokji RS and List AF: Role of
lenalidomide in the treatment of myelodysplastic syndromes. Semi
Oncol. 38:648–657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giagounidis AA: Lenalidomide for del(5q)
and non-del(5q) myelodysplastic syndromes. Semin Hematol.
49:312–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sugimoto Y, Sekeres MA, Makishima H, et
al: Cytogenetic and molecular predictors of response in patients
with myeloid malignancies without del[5q] treated with
lenalidomide. J Hematol Oncol. 5:42012.PubMed/NCBI
|
|
18
|
Sibon D, Cannas G, Baracco F, et al;
Groupe Francophone des Myélodysplasies. Lenalidomide in lower-risk
myelodysplastic syndromes with karyotypes other than deletion 5q
and refractory to erythropoiesis-stimulating agents. Br J Haematol.
156:619–625. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fenaux P, Giagounidis A, Selleslag DL, et
al: RBC transfusion independence and safety profile of lenalidomide
5 or 10 mg in Pts with low-or Int-1-risk MDS with Del5q: Results
from a randomized phase III trial (MDS-004). Blood (ASH Annual
Meeting abstracts). 114:9442009.
|
|
20
|
Yang X, Brandenburg NA, Freeman J, et al:
Venous thromboembolism in myelodysplastic syndrome patients
receiving lenalidomide: results from postmarketing surveillance and
data mining techniques. Clin Drug Investig. 29:161–171. 2009.
View Article : Google Scholar
|
